Kellie Jones, MD
Pulmonary Disease · Oklahoma City, OKNPI 1598733784
Payments from drug & device makers
Across 41 payments — averaging $20.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$178
- Sunovion Pharmaceuticals Inc.$150
- GSK$109
- Actelion Pharmaceuticals US, Inc.$89
- Boehringer Ingelheim$45
- Ambu Inc.$38
- plus $222 from 11 others
What the payments were for
- Food & beverage$830100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 8 | $178 |
| Sunovion Pharmaceuticals Inc. | 7 | $150 |
| GSK | 7 | $109 |
| Actelion Pharmaceuticals US, Inc. | 3 | $89 |
| Boehringer Ingelheim | 2 | $45 |
| Ambu Inc. | 1 | $38 |
| Insmed, Inc. | 2 | $38 |
| Genentech USA, Inc. | 2 | $30 |
| AbbVie | 1 | $24 |
| Novartis | 1 | $23 |
| Vifor Pharma, Inc. | 1 | $20 |
| Chiesi USA, Inc. | 1 | $19 |
| Edwards Lifesciences | 1 | $18 |
| Photocure Inc | 1 | $16 |
| Merck | 1 | $12 |
| AstraZeneca | 1 | $11 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $11 |
How this compares
$830 in reported general payments places this provider in the 25th percentile of 133 pulmonary disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 54 | $1,333,882 |
| Ursodiol | 13 | $1,083 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 16 | $934 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Oklahoma City
- John KingreyOklahoma City$2.4M
- Jad KebbeOklahoma City$1.5M
- Karen AllenOklahoma City$202K
- Robert GordonOklahoma City$160K
- Nicholas ShelburneOklahoma City$102K
- Tony AbdoOklahoma City$91K
- Fawad ChaudryOklahoma City$80K
- Loan NguyenOklahoma City$76K
- Maroun TawkOklahoma City$62K
- Adam PrzebindaOklahoma City$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.